0.8853
Precedente Chiudi:
$0.9303
Aprire:
$0.91
Volume 24 ore:
338.17K
Relative Volume:
0.37
Capitalizzazione di mercato:
$117.12M
Reddito:
$3.25M
Utile/perdita netta:
$-116.80M
Rapporto P/E:
-0.2903
EPS:
-3.05
Flusso di cassa netto:
$-98.17M
1 W Prestazione:
-28.02%
1M Prestazione:
-2.28%
6M Prestazione:
-29.74%
1 anno Prestazione:
-78.14%
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Nome
Rapt Therapeutics Inc
Settore
Industria
Telefono
(650) 489-9000
Indirizzo
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Confronta RAPT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RAPT
Rapt Therapeutics Inc
|
0.8853 | 162.72M | 3.25M | -116.80M | -98.17M | -3.05 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-22 | Ripresa | H.C. Wainwright | Buy |
2024-12-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2024-11-13 | Downgrade | Stifel | Buy → Hold |
2024-11-11 | Downgrade | JP Morgan | Neutral → Underweight |
2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
2024-05-14 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2024-05-10 | Downgrade | Barclays | Overweight → Equal Weight |
2024-05-10 | Downgrade | Guggenheim | Buy → Neutral |
2024-02-22 | Downgrade | UBS | Buy → Neutral |
2024-02-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
2024-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
2024-02-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
2024-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2024-02-16 | Iniziato | Evercore ISI | Outperform |
2024-02-15 | Iniziato | Wolfe Research | Outperform |
2023-09-14 | Iniziato | Berenberg | Buy |
2023-08-09 | Iniziato | Stifel | Buy |
2023-06-15 | Iniziato | Barclays | Overweight |
2023-01-04 | Iniziato | Guggenheim | Buy |
2022-12-01 | Iniziato | Goldman | Buy |
2022-09-21 | Iniziato | CapitalOne | Overweight |
2022-05-24 | Ripresa | Cantor Fitzgerald | Overweight |
2021-12-09 | Iniziato | JP Morgan | Overweight |
2021-08-12 | Iniziato | SVB Leerink | Outperform |
2021-06-21 | Iniziato | Piper Sandler | Overweight |
2020-06-01 | Iniziato | H.C. Wainwright | Buy |
2020-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
2020-04-13 | Iniziato | ROTH Capital | Buy |
2019-11-25 | Iniziato | BMO Capital Markets | Outperform |
2019-11-25 | Iniziato | UBS | Buy |
2019-11-25 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Rapt Therapeutics Inc Borsa (RAPT) Ultime notizie
RAPT Therapeutics Faces Nasdaq Delisting Notice - TipRanks
What is HC Wainwright’s Forecast for RAPT Q2 Earnings? - Defense World
UBS Group Cuts RAPT Therapeutics (NASDAQ:RAPT) Price Target to $1.00 - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by HC Wainwright - Defense World
D. E. Shaw & Co. Inc. Sells 278,173 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Stock: HC Wainwright & Co. Announces New Price Target | RAP - GuruFocus
UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Stock News - GuruFocus
RAPT Analyst Update: UBS Adjusts Price Target to $1 | RAPT Stock News - GuruFocus
Rapt Therapeutics (RAPT) Receives Buy Rating with Promising Outl - GuruFocus
UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Sto - GuruFocus
Rapt Therapeutics (RAPT) Receives Buy Rating with Promising Outlook | RAPT Stock News - GuruFocus
UBS cuts Rapt Therapeutics stock target to $1 from $2 By Investing.com - Investing.com UK
Comerica Bank Purchases Shares of 58,040 RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Dimensional Fund Advisors LP Sells 105,231 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World
RAPT Therapeutics Reports Improved Q1 2025 Results - TipRanks
RAPT Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Reports Third Quarter 2024 Financial Results - ADVFN
RAPT Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Has $584,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
JPMorgan Chase & Co. Raises Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
There is no way RAPT Therapeutics Inc (RAPT) can keep these numbers up - Sete News
A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com
Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
RAPT Therapeutics Inc (RAPT) is a good investment, but the stock may be overvalued - uspostnews.com
Stock Surge: RAPT Therapeutics Inc (RAPT) Closes at 0.79, Marking a -1.32 Increase/Decrease - DWinneX
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth? - Yahoo Finance
RAPT stock touches 52-week low at $0.78 amid sharp annual decline - Investing.com Canada
RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Rapt Therapeutics appoints Jessica Savage as VP, clinical development - TipRanks
RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus
RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire
Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World
Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada
RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks
RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks
RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks
Rapt Therapeutics Inc Azioni (RAPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):